ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Mortimer Berkowitz IIIDIRECTOR ELECTIONSISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Quentin BlackfordDIRECTOR ELECTIONSISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors David DemskiDIRECTOR ELECTIONSISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Karen K. McGinnisDIRECTOR ELECTIONSISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Patrick S. MilesDIRECTOR ELECTIONSISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors David R. PelizzonDIRECTOR ELECTIONSISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Keith ValentineDIRECTOR ELECTIONSISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To approve the Alphatec Holdings, Inc. 2026 Equity Incentive Plan;COMPENSATIONISSUER282000AGAINST28200AGAINST128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To approve the Alphatec Holdings, Inc. 2026 Employee Stock Purchase Plan; andCAPITAL STRUCTUREISSUER282000FOR28200FOR128S000038991 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER282000AGAINST28200AGAINST128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026DIRECTOR: Dr. Peter FarrellDIRECTOR ELECTIONSISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026DIRECTOR: Joseph E. PayneDIRECTOR ELECTIONSISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026DIRECTOR: James BarlowDIRECTOR ELECTIONSISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026DIRECTOR: Dr. Edward W. HolmesDIRECTOR ELECTIONSISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026DIRECTOR: Dr. Magda MarquetDIRECTOR ELECTIONSISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026DIRECTOR: Dr. Jing L. MarantzDIRECTOR ELECTIONSISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026DIRECTOR: Dr. John MarkelsDIRECTOR ELECTIONSISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026DIRECTOR: Dr. Moncef SlaouiDIRECTOR ELECTIONSISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026Approval, by non-binding advisory vote, of the resolution approving the Company's Named Executive Officer compensation, as provided in Proposal Number 2 of the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER133700FOR13370FOR128S000038991 ARCTURUS THERAPEUTICS, HOLDINGS INC.03969T109US03969T109706/05/2026Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER133700FOR13370FOR128S000038991 ATOMERA INCORPORATED04965B100US04965B100805/12/2026DIRECTOR: John GerberDIRECTOR ELECTIONSISSUER40039600ABSTAIN400AGAINST128S000038991 ATOMERA INCORPORATED04965B100US04965B100805/12/2026DIRECTOR: Scott BibaudDIRECTOR ELECTIONSISSUER40039600ABSTAIN400AGAINST128S000038991 ATOMERA INCORPORATED04965B100US04965B100805/12/2026DIRECTOR: Steve ShevickDIRECTOR ELECTIONSISSUER40039600ABSTAIN400AGAINST128S000038991 ATOMERA INCORPORATED04965B100US04965B100805/12/2026DIRECTOR: Duy-Loan LeDIRECTOR ELECTIONSISSUER40039600ABSTAIN400AGAINST128S000038991 ATOMERA INCORPORATED04965B100US04965B100805/12/2026DIRECTOR: Suja RamnathDIRECTOR ELECTIONSISSUER40039600FOR400FOR128S000038991 ATOMERA INCORPORATED04965B100US04965B100805/12/2026To ratify the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER40039600AGAINST400AGAINST128S000038991 ATOMERA INCORPORATED04965B100US04965B100805/12/2026To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the Corporation's authorized common stock to 95 million shares.CAPITAL STRUCTUREISSUER40039600AGAINST400AGAINST128S000038991 ATOMERA INCORPORATED04965B100US04965B100805/12/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement to be filed for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER40039600AGAINST400AGAINST128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026RE-ELECT: GLENN J. MULLAN AS A DIRECTORDIRECTOR ELECTIONSISSUER4424800FOR442480FOR128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026RE-ELECT: JEAN-MARC LULIN AS A DIRECTORDIRECTOR ELECTIONSISSUER4424800FOR442480FOR128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026RE-ELECT: JEAN-CHARLES POTVIN AS A DIRECTORDIRECTOR ELECTIONSISSUER4424800FOR442480FOR128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026RE-ELECT: JACQUES SIMONEAU AS A DIRECTORDIRECTOR ELECTIONSISSUER4424800FOR442480FOR128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026RE-ELECT: MICHEL BRUNET AS A DIRECTORDIRECTOR ELECTIONSISSUER4424800FOR442480FOR128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026RE-ELECT: CHRISTIANE BERGEVIN AS A DIRECTORDIRECTOR ELECTIONSISSUER4424800FOR442480FOR128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026RE-ELECT: VANESSA LAPLANTE AS A DIRECTORDIRECTOR ELECTIONSISSUER4424800FOR442480FOR128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026TO APPOINT AUDITORS OF THE CORPORATION AND AUTHORIZE THE BOARD OF DIRECTORS TO FIX THE AUDITORS' REMUNERATIONAUDIT-RELATEDISSUER4424800FOR442480FOR128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026PLEASE NOTE RESOLUTION 1.1 FAVOR OR ABSTAIN ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER4424800128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026PLEASE NOTE RESOLUTION 1.2 FAVOR OR ABSTAIN ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER4424800128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026PLEASE NOTE RESOLUTION 1.3 FAVOR OR ABSTAIN ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER4424800128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026PLEASE NOTE RESOLUTION 1.4 FAVOR OR ABSTAIN ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER4424800128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026PLEASE NOTE RESOLUTION 1.5 FAVOR OR ABSTAIN ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER4424800128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026PLEASE NOTE RESOLUTION 1.6 FAVOR OR ABSTAIN ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER4424800128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026PLEASE NOTE RESOLUTION 1.7 FAVOR OR ABSTAIN ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER4424800128S000038991 AZIMUT EXPLORATION INC301950101CA301950101202/26/2026PLEASE NOTE VOTING ABSTAIN RESOLUTIONS 1.1 TO 1.7 AND 2 WILL BE TRANSPOSED AS A WITHHOLD VOTE, TO ACCOMMODATE DIFFERING PRACTICES AND ALIGN WITH THE OFFICIAL ISSUER ANNOUNCEMENT.OTHEROther Voting MattersISSUER4424800128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Marcus A. LemonisDIRECTOR ELECTIONSISSUER410000WITHHOLD41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Joanna C. BurkeyDIRECTOR ELECTIONSISSUER410000WITHHOLD41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Barclay F. CorbusDIRECTOR ELECTIONSISSUER410000WITHHOLD41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; William B. Nettles, Jr.DIRECTOR ELECTIONSISSUER410000WITHHOLD41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Debra G. PerelmanDIRECTOR ELECTIONSISSUER410000WITHHOLD41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Dr. Robert J. ShapiroDIRECTOR ELECTIONSISSUER410000WITHHOLD41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Joseph J. Tabacco, Jr.DIRECTOR ELECTIONSISSUER410000WITHHOLD41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER410000FOR41000FOR128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The approval, on an advisory (non-binding) basis, of the compensation paid by the Company to its named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER410000AGAINST41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock.CAPITAL STRUCTUREISSUER410000AGAINST41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4 and/or Proposal 6.CORPORATE GOVERNANCEISSUER410000AGAINST41000AGAINST128S000038991 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The approval of an amendment and restatement of the Company's Amended and Restated 2005 Equity Incentive Plan.COMPENSATIONISSUER410000AGAINST41000AGAINST128S000038991 CABALETTA BIO, INC.12674W109US12674W109906/09/2026To elect two class I directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Scott Brun, M.D.DIRECTOR ELECTIONSISSUER600000FOR60000FOR128S000038991 CABALETTA BIO, INC.12674W109US12674W109906/09/2026To elect two class I directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. Shawn Tomasello, MBADIRECTOR ELECTIONSISSUER600000FOR60000FOR128S000038991 CABALETTA BIO, INC.12674W109US12674W109906/09/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER600000FOR60000FOR128S000038991 CABALETTA BIO, INC.12674W109US12674W109906/09/2026To approve an amendment to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan.COMPENSATIONISSUER600000AGAINST60000AGAINST128S000038991 CABALETTA BIO, INC.12674W109US12674W109906/09/2026To approve an amendment to our Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 600,000,000.CAPITAL STRUCTUREISSUER600000AGAINST60000AGAINST128S000038991 CABALETTA BIO, INC.12674W109US12674W109906/09/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER600000AGAINST60000AGAINST128S000038991 CABALETTA BIO, INC.12674W109US12674W109906/09/2026To approve a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 3 and Proposal 4.CORPORATE GOVERNANCEISSUER600000AGAINST60000AGAINST128S000038991 CANTALOUPE, INC.138103106US138103106109/04/2025To approve and adopt the Agreement and Plan of Merger, dated as of June 15, 2025, by and among Cantaloupe, Inc., 365 Retail Markets, LLC, Catalyst Holdco I, Inc., Catalyst Holdco II, Inc. and Catalyst MergerSub Inc., as it may be amended from time to time (the ''Merger Agreement''), under which Catalyst MergerSub Inc. will merge with and into Cantaloupe, Inc., with Cantaloupe, Inc. surviving the merger (the ''Merger'') as a wholly owned subsidiary of Catalyst Holdco II, Inc.CORPORATE GOVERNANCEISSUER323250FOR32325FOR128S000038991 CANTALOUPE, INC.138103106US138103106109/04/2025To approve, by a non-binding, advisory vote, the compensation arrangements that will or may become payable to Cantaloupe, Inc.'s named executive officers in connection with the Merger.SECTION 14A SAY-ON-PAY VOTESISSUER323250FOR32325FOR128S000038991 CANTALOUPE, INC.138103106US138103106109/04/2025To approve the adjournment of the Special Meeting of Cantaloupe, Inc's shareholders (the ''Special Meeting'') from time to time, if necessary or appropriate (as determined by the board of directors of Cantaloupe, Inc. or the chairperson of the meeting) to solicit additional proxies to vote in favor of the proposal to approve and adopt the Merger Agreement, in the event that there are insufficient votes at the time of the Special Meeting to establish a quorum or approve and adopt the Merger Agreement or with 365 Retail Markets, LLC's prior written consent.CORPORATE GOVERNANCEISSUER323250FOR32325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Douglas G. BergeronDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Lisa P. BairdDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Ian HarrisDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Jacob LammDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Michael K. PassillaDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Ellen RicheyDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Anne M. SmallingDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Ravi VenkatesanDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Election of nine directors nominated by the Company's Board of Directors to serve until the next Annual Meeting of Shareholders. Shannon S. WarrenDIRECTOR ELECTIONSISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER183250FOR18325FOR128S000038991 CANTALOUPE, INC.138103106US138103106111/19/2025Ratification of the appointment of Deloitte & Touche LLP ("Deloitte") as the Company's independent registered public accountants for the fiscal year ending June 30, 2026.AUDIT-RELATEDISSUER183250FOR18325FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Business Combination Proposal - to ratify, approve, adopt and confirm the Business Combination Agreement dated as of October 27, 2025 (as amended or restated from time to time, the ''Business Combination Agreement''), by and among CEPT, Securitize, Inc. (''Securitize''), Securitize Holdings, Inc. (''PubCo''), Senna Merger Sub, Inc. (''Company Merger Sub'') and Pinecrest Merger Sub (''SPAC Merger Sub''), pursuant to which: (i) CEPT will merge with and into SPAC Merger Sub, with SPAC Merger Sub continuing as the surviving entity (the ''CEPT Merger''); and (ii) at least two (2) hours after the CEPT Merger, Company Merger Sub will merge with and into Securitize, with Securitize continuing as the surviving company (the ''PubCo Merger'' and together with the SPAC Merger, the ''Mergers''). All of the transactions contemplated by the Business Combination Agreement and any ancillary documents contemplated therein are collectively referred to as the ''Business Combination''.CORPORATE GOVERNANCEISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Merger Proposal - to approve and authorize (a) the CEPT Merger, with SPAC Merger Sub continuing as the surviving entity and the plan of merger to be entered into by SPAC Merger Sub and CEPT (the ''CEPT Plan of Merger''), and (b) upon the effective date of the CEPT Merger, (i) the memorandum and articles of association of the surviving entity in the form annexed to the CEPT Plan of Merger be approved in all respects, and (ii) the authorized share capital of CEPT be amended from $55,500 divided into 500,000,000 Class A Ordinary shares of a par value of $0.0001 each, 50,000,000 Class B ordinary shares of a par value of $0.0001 each and 5,000,000 preference shares of a par value of $0.0001 each to $50,000 divided to 500,000,000 ordinary shares of a nominal or par value of $0.0001 each.CORPORATE GOVERNANCEISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide for a classified board of directors of PubCo (the ''PubCo Board'') with three classes, designated Class I, Class II and Class III, with each class being up for election on a rolling three-year basis, subject to an initial phase-in period;SHAREHOLDER RIGHTS AND DEFENSESISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will require that the PubCo Board is elected by a plurality of the votes cast in respect of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. There shall be no cumulative voting in the election of directors;CORPORATE GOVERNANCEISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide that special meetings of the shareholders may be called only by the PubCo Board acting pursuant to a resolution adopted by a majority of the PubCo Board or by the Chair of the PubCo Board;CORPORATE GOVERNANCEISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide that a majority of the PubCo Board shall constitute a quorum for the transaction of business at any meeting of the PubCo Board and, except as otherwise expressly required by law or by the PubCo Charter, the act of a majority of the directors present at a meeting at which a quorum is present shall be the act of the PubCo Board. When a meeting is adjourned to another time or place (whether or not a quorum is present), notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the PubCo Board may transact any business which might have been transacted at the original meeting. If a quorum shall not be present at any meeting of the PubCo Board, the directors present thereat shall adjourn the meeting, from time to time, without notice other than announcement at the meeting, until a quorum shall be present;CORPORATE GOVERNANCEISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide that (a) PubCo must give written notice to shareholders entitled to vote at a meeting not less than ten (10) and not more than sixty (60) days before the date of such meeting, with such notice complying with any other requirements set by Delaware law or the Proposed Organizational Documents, and (b) at an annual meeting of the shareholders, shareholder proposals must be brought, among other things, (i) pursuant to PubCo's notice of meeting (or any supplement thereto); (ii) by or at the direction of the PubCo Board or any committee thereof duly authorized; (iii) as may be provided in the certificate of designations for any class or series of preferred stock or (iv) by any shareholder of PubCo who (A) is a shareholder of record at the time of the giving of the notice, (B) is entitled to vote at such meeting and (C) complies with the procedures set forth in the PubCo Bylaws. Additionally, for proposals to be properly brought before an annual meeting of stockholders by a stockholder, the stockholder must have given timely notice thereof in writing to the Secretary of PubCo and any such proposed business (other than the nominations of persons for election to the PubCo Board) must constitute a proper matter for stockholder action;CORPORATE GOVERNANCEISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide for an exclusive forum for any filing, adjudication and trial of any action as set forth in the PubCo Charter, of the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware); provided that unless the PubCo consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for any action asserting a cause of action arising under the Securities Act of 1933, or any rule or regulation promulgated thereunder, shall be the federal district courts of the United States.CORPORATE GOVERNANCEISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Nasdaq Proposal - to approve a proposal for the purposes of complying with the applicable provisions of Nasdaq Rule 5635, the issuance (i) by CEPT of up to 535,000 CEPT Class A Ordinary Shares issuable in repayment of that certain promissory note in the aggregate principal amount of up to $1,750,000 entered into by CEPT in favor of Cantor EP Holdings II, LLC (the ''Sponsor'') on May 1, 2025 and that certain promissory note in the aggregate principal amount of up to $3,600,000 entered into by CEPT in favor of the Sponsor on May 1, 2025, and (b) up to 22,500,000 CEPT Class A Ordinary Shares (the ''PIPE Shares'') issuable to certain investors (the ''PIPE Investors'') upon consummation of a private placement immediately prior to the CEPT Merger (the ''PIPE Investment''), and (ii) by PubCo of (a) up to 156,675,245 shares of PubCo common stock in the Mergers (including up to 6,250,000 earnout shares), (b) an additional number of shares of PubCo common stock equal to 10% of the total number of shares of PubCo's Common Stock outstanding immediately following closing of the Business Combination that will, upon closing of the Business Combination, be reserved for issuance pursuant to PubCo's incentive plan and PubCo's employee stock purchase plan plus an additional number of shares of PubCo common stock that may become issuable pursuant to the exercise or settlement of certain options and restricted stock units to acquire Securitize common stock being assumed by PubCo in the Business Combination, and (c) up to 3,829,432 shares of PubCo common stock issuable upon the exercise of certain warrants held by J Digital 6 LLC, in each case, to the extent such issuances would require shareholder approval under Nasdaq Rule 5635.CAPITAL STRUCTUREISSUER280000FOR28000FOR128S000038991 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Adjournment Proposal - to approve a proposal to adjourn the Meeting to a later date or dates to be determined by the Chairman of the Meeting, if it is determined by CEPT that additional time is necessary or appropriate to complete the Business Combination or for any other reason.CORPORATE GOVERNANCEISSUER280000FOR28000FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: F. E. Cohen MD, D. PhilDIRECTOR ELECTIONSISSUER128000FOR12800FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: R. Bryan RiggsbeeDIRECTOR ELECTIONSISSUER128000FOR12800FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: Suresh GunasekaranDIRECTOR ELECTIONSISSUER128000FOR12800FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: Michael D. GoldbergDIRECTOR ELECTIONSISSUER128000FOR12800FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: John W. HannaDIRECTOR ELECTIONSISSUER128000FOR12800FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER128000FOR12800FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026Approval, on an advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER128000FOR12800FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026To vote, on an advisory basis, the frequency of advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1280001 YEAR12800FOR128S000038991 CAREDX, INC.14167L103US14167L103506/11/2026Approval of an amendment to the 2024 Equity Incentive Plan.COMPENSATIONISSUER128000AGAINST12800AGAINST128S000038991 CARTESIAN THERAPEUTICS, INC.816212302US816212302506/12/2026DIRECTOR: Michael Singer, MD, PhDDIRECTOR ELECTIONSISSUER20018300ABSTAIN200AGAINST128S000038991 CARTESIAN THERAPEUTICS, INC.816212302US816212302506/12/2026DIRECTOR: Timothy A. Springer PhDDIRECTOR ELECTIONSISSUER20018300ABSTAIN200AGAINST128S000038991 CARTESIAN THERAPEUTICS, INC.816212302US816212302506/12/2026DIRECTOR: Patrick Zenner, MBADIRECTOR ELECTIONSISSUER20018300ABSTAIN200AGAINST128S000038991 CARTESIAN THERAPEUTICS, INC.816212302US816212302506/12/2026To approve, on a non-binding and advisory basis, a resolution approving the compensation of Cartesian Therapeutics, Inc.'s named executive officers, as described in the accompanying proxy statement under "Executive and Director Compensation."SECTION 14A SAY-ON-PAY VOTESISSUER20018300AGAINST200AGAINST128S000038991 CARTESIAN THERAPEUTICS, INC.816212302US816212302506/12/2026To ratify the appointment of Ernst & Young LLP as Cartesian Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER20018300FOR200FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Richard E. BullerDIRECTOR ELECTIONSISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: David F. DalveyDIRECTOR ELECTIONSISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Leo T. FurchtDIRECTOR ELECTIONSISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Lance G. LaingDIRECTOR ELECTIONSISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Polly A. MurphyDIRECTOR ELECTIONSISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Richard J. NigonDIRECTOR ELECTIONSISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Charles R. RompDIRECTOR ELECTIONSISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Brian F. SullivanDIRECTOR ELECTIONSISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026To ratify the appointment of Boulay PLLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026To approve, on an advisory basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026To approve the Celcuity Inc. 2026 Stock Incentive Plan.COMPENSATIONISSUER116090FOR11609FOR128S000038991 CELCUITY INC.15102K100US15102K100705/14/2026To approve the Celcuity Inc. Amended and Restated Employee Stock Purchase Plan.CAPITAL STRUCTUREISSUER116090FOR11609FOR128S000038991 CERUS CORPORATION157085101US157085101406/02/2026DIRECTOR: William M. GreenmanDIRECTOR ELECTIONSISSUER1630000FOR163000FOR128S000038991 CERUS CORPORATION157085101US157085101406/02/2026DIRECTOR: Ann LucenaDIRECTOR ELECTIONSISSUER1630000FOR163000FOR128S000038991 CERUS CORPORATION157085101US157085101406/02/2026Equity Plan Proposal - The approval of an amendment and restatement of the Company's 2024 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 10 million shares and to make certain other changes thereto as described further in the accompanying Proxy Statement.COMPENSATIONISSUER1630000AGAINST163000AGAINST128S000038991 CERUS CORPORATION157085101US157085101406/02/2026Advisory Votes on Executive Compensation - The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1630000FOR163000FOR128S000038991 CERUS CORPORATION157085101US157085101406/02/2026Independent Registered Public Accounting Firm - The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1630000FOR163000FOR128S000038991 CODEXIS, INC.192005106US192005106706/17/2026DIRECTOR: S. G. Dilly, MBBS, PhD.DIRECTOR ELECTIONSISSUER1568750ABSTAIN156875AGAINST128S000038991 CODEXIS, INC.192005106US192005106706/17/2026DIRECTOR: Raymond De Vré, Ph.D.DIRECTOR ELECTIONSISSUER1568750ABSTAIN156875AGAINST128S000038991 CODEXIS, INC.192005106US192005106706/17/2026DIRECTOR: Rahul Singhvi, Sc.D.DIRECTOR ELECTIONSISSUER1568750FOR156875FOR128S000038991 CODEXIS, INC.192005106US192005106706/17/2026To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1568750FOR156875FOR128S000038991 CODEXIS, INC.192005106US192005106706/17/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1568750AGAINST156875AGAINST128S000038991 COMSCORE, INC.20564W204US20564W204412/19/2025The approval, in accordance with Nasdaq Listing Rules 5635(b) and 5635(d), of the issuance of common stock and Series C Convertible Preferred Stock ("Series C Preferred Stock") to Charter Communications Holding Company, LLC, Liberty Broadband Corporation and Pine Investor, LLC (the "Preferred Stockholders") in accordance with the Stock Exchange Agreements between the Company and each of the Preferred Stockholders (the "Share Issuance").CAPITAL STRUCTUREISSUER793050FOR79305FOR128S000038991 COMSCORE, INC.20564W204US20564W204412/19/2025The approval of the Stock Exchange Agreements, the Certificate of Designations of the Series C Preferred Stock, the Stockholder Support Agreements with the Preferred Stockholders, an amendment to the Registration Rights Agreement with the Preferred Stockholders, the Second Amended and Restated Stockholders Agreement with the Preferred Stockholders, and the Exchange (as defined in the Stock Exchange Agreements) by a vote of the "disinterested stockholders" as defined in Delaware law (the "Disinterested Stockholder Approval").OTHERCompany Specific Organization RelatedISSUER793050FOR79305FOR128S000038991 COMSCORE, INC.20564W204US20564W204412/19/2025The adoption of an amendment to the Amended and Restated Certificate of Incorporation to permit the Share Issuance and authorize a sufficient number of shares of common stock and preferred stock of the Company (the "COI Amendment").CAPITAL STRUCTURECORPORATE GOVERNANCEISSUER793050FOR79305FOR128S000038991 COMSCORE, INC.20564W204US20564W204412/19/2025The approval of one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve the Share Issuance, the Disinterested Stockholder Approval and/or the COI Amendment.CORPORATE GOVERNANCEISSUER793050FOR79305FOR128S000038991 COMSCORE, INC.20564W204US20564W204406/16/2026DIRECTOR: David KlineDIRECTOR ELECTIONSISSUER608050ABSTAIN60805AGAINST128S000038991 COMSCORE, INC.20564W204US20564W204406/16/2026DIRECTOR: Brian WendlingDIRECTOR ELECTIONSISSUER608050ABSTAIN60805AGAINST128S000038991 COMSCORE, INC.20564W204US20564W204406/16/2026The approval, on a non-binding advisory basis, of the compensation paid to the company's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER608050FOR60805FOR128S000038991 COMSCORE, INC.20564W204US20564W204406/16/2026The ratification of the appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026AUDIT-RELATEDISSUER608050FOR60805FOR128S000038991 COMSCORE, INC.20564W204US20564W204406/16/2026The approval of an amendment to the Amended and Restated 2018 Equity and Incentive Compensation Plan to increase the number of shares of the company's common stock available for grant by 3,000,000COMPENSATIONISSUER608050AGAINST60805AGAINST128S000038991 CREDITRISKMONITOR.COM, INC.225426105US225426105809/18/2025DIRECTOR: Jerome S. FlumDIRECTOR ELECTIONSISSUER00128S000038991 CREDITRISKMONITOR.COM, INC.225426105US225426105809/18/2025DIRECTOR: Lisa ReismanDIRECTOR ELECTIONSISSUER00128S000038991 CREDITRISKMONITOR.COM, INC.225426105US225426105809/18/2025DIRECTOR: Joshua M. FlumDIRECTOR ELECTIONSISSUER00128S000038991 CREDITRISKMONITOR.COM, INC.225426105US225426105809/18/2025DIRECTOR: Lawrence FensterstockDIRECTOR ELECTIONSISSUER00128S000038991 CREDITRISKMONITOR.COM, INC.225426105US225426105809/18/2025To approve the compensation paid to the Company's named executive officers on a non-binding advisory basis as described in the Proxy Statement for the 2025 Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER00128S000038991 CREDITRISKMONITOR.COM, INC.225426105US225426105809/18/2025To ratify the selection of CohnReznick LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.AUDIT-RELATEDISSUER00128S000038991 CREDITRISKMONITOR.COM, INC.225426105US225426105809/18/2025To hold an advisory, non-binding vote to determine the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER00128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Michael Giuffre, M.D.DIRECTOR ELECTIONSISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Richard Kuntz, M.D., M.Sc.DIRECTOR ELECTIONSISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Tanya N. LewisDIRECTOR ELECTIONSISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Daniel J. O'ConnorDIRECTOR ELECTIONSISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. James ParsonsDIRECTOR ELECTIONSISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Rick PaulsDIRECTOR ELECTIONSISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Charles Semba, M.D.DIRECTOR ELECTIONSISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To approve, on an advisory (non-binding) basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2593044800FOR25930FOR128S000038991 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To approve an amendment and restatement of the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan.COMPENSATIONISSUER2593044800FOR25930FOR128S000038991 ENERGOUS CORPORATION29272C301US29272C301606/11/2026DIRECTOR: David RobersonDIRECTOR ELECTIONSISSUER120000FOR12000FOR128S000038991 ENERGOUS CORPORATION29272C301US29272C301606/11/2026DIRECTOR: Mallorie BurakDIRECTOR ELECTIONSISSUER120000FOR12000FOR128S000038991 ENERGOUS CORPORATION29272C301US29272C301606/11/2026DIRECTOR: J. Michael DodsonDIRECTOR ELECTIONSISSUER120000FOR12000FOR128S000038991 ENERGOUS CORPORATION29272C301US29272C301606/11/2026DIRECTOR: Rahul PatelDIRECTOR ELECTIONSISSUER120000FOR12000FOR128S000038991 ENERGOUS CORPORATION29272C301US29272C301606/11/2026Ratify the appointment of BPM LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER120000FOR12000FOR128S000038991 ENERGOUS CORPORATION29272C301US29272C301606/11/2026Approve the Energous Corporation Amended and Restated 2024 Equity Incentive Plan.COMPENSATIONISSUER120000FOR12000FOR128S000038991 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026Election of Class I Directors J. Martin CarrollDIRECTOR ELECTIONSISSUER4043058570WITHHOLD40430AGAINST128S000038991 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026Election of Class I Directors Sheldon L. KoenigDIRECTOR ELECTIONSISSUER4043058570WITHHOLD40430AGAINST128S000038991 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026To approve the non-binding advisory resolution on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4043058570AGAINST40430AGAINST128S000038991 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER4043058570FOR40430FOR128S000038991 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan.COMPENSATIONISSUER4043058570AGAINST40430AGAINST128S000038991 FREIGHTOS LIMITEDG51405101KYG51405101312/15/2025Election of Class II Director for a three-year term expiring at the third succeeding annual general meeting of the Company (to be held in 2028): Udo LangeDIRECTOR ELECTIONSISSUER2260000FOR226000FOR128S000038991 FREIGHTOS LIMITEDG51405101KYG51405101312/15/2025Election of Class II Director for a three-year term expiring at the third succeeding annual general meeting of the Company (to be held in 2028): Rotem HershkoDIRECTOR ELECTIONSISSUER2260000FOR226000FOR128S000038991 FREIGHTOS LIMITEDG51405101KYG51405101312/15/2025Election of Class II Director for a three-year term expiring at the third succeeding annual general meeting of the Company (to be held in 2028): Michael SchaecherDIRECTOR ELECTIONSISSUER2260000FOR226000FOR128S000038991 FREIGHTOS LIMITEDG51405101KYG51405101312/15/2025Ratification of the re-appointment of Kost Forer Gabbay & Kasierer, a member firm of EY Global Limited, as the independent auditors of the Company for 2025 and authorization of the audit committee of the Board of Directors to fix the auditors' compensation.AUDIT-RELATEDISSUER2260000FOR226000FOR128S000038991 HARROW INC.415858109US415858109406/18/2026DIRECTOR: Mark L. BaumDIRECTOR ELECTIONSISSUER102470FOR10247FOR128S000038991 HARROW INC.415858109US415858109406/18/2026DIRECTOR: Adrienne L. GravesDIRECTOR ELECTIONSISSUER102470FOR10247FOR128S000038991 HARROW INC.415858109US415858109406/18/2026DIRECTOR: Lauren P. SilvernailDIRECTOR ELECTIONSISSUER102470FOR10247FOR128S000038991 HARROW INC.415858109US415858109406/18/2026DIRECTOR: Perry J. SternbergDIRECTOR ELECTIONSISSUER102470FOR10247FOR128S000038991 HARROW INC.415858109US415858109406/18/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as presented in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER102470AGAINST10247AGAINST128S000038991 HARROW INC.415858109US415858109406/18/2026Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER102470FOR10247FOR128S000038991 HERON THERAPEUTICS, INC.427746102US427746102010/13/2025To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's common stock in connection with the conversion of convertible senior unsecured promissory notes due 2031 held by several non-affiliated purchasers, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of stock issued and outstanding prior to such issuance.CAPITAL STRUCTUREISSUER82081140FOR820FOR128S000038991 HERON THERAPEUTICS, INC.427746102US427746102010/13/2025To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of the common stock issued and outstanding prior to such issuance.CAPITAL STRUCTUREISSUER82081140FOR820FOR128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Craig CollardDIRECTOR ELECTIONSISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Tom CusackDIRECTOR ELECTIONSISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Sharmila Dissanaike, M.D., FACS, FCCMDIRECTOR ELECTIONSISSUER2169600FOR216960FOR128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Craig JohnsonDIRECTOR ELECTIONSISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Michael KasetaDIRECTOR ELECTIONSISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Adam MorganDIRECTOR ELECTIONSISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Christian WaageDIRECTOR ELECTIONSISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To ratify the appointment of Withum as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2169600FOR216960FOR128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To approve, on a nonbinding advisory basis, compensation paid to our Named Executive Officers during the fiscal year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To approve the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares.COMPENSATIONISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To amend the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares.CAPITAL STRUCTUREISSUER2169600AGAINST216960AGAINST128S000038991 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To ratify, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan.SHAREHOLDER RIGHTS AND DEFENSESISSUER2169600AGAINST216960AGAINST128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025DIRECTOR: Jeffrey E. EberweinDIRECTOR ELECTIONSISSUER499540ABSTAIN49954AGAINST128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025DIRECTOR: Mimi K. DrakeDIRECTOR ELECTIONSISSUER499540ABSTAIN49954AGAINST128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025DIRECTOR: Connia M. NelsonDIRECTOR ELECTIONSISSUER499540ABSTAIN49954AGAINST128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025DIRECTOR: Robert PearseDIRECTOR ELECTIONSISSUER499540ABSTAIN49954AGAINST128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025To approve, by advisory vote, the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER499540ABSTAIN49954AGAINST128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025To ratify the appointment of Wolf & Company, P.C. as independent registered public accounting firm to audit the Company's financial statements for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER499540FOR49954FOR128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025To approve the proposed amendment to the Hudson Global, Inc. 2009 Incentive Stock and Awards Plan to increase the authorized shares of Company Common Stock issuable under the Plan by 400,000 shares, and to permit the issuance of up to 175,000 shares of Company Preferred Stock.COMPENSATIONISSUER499540AGAINST49954AGAINST128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025To approve the issuance of shares of common stock of Hudson, which will represent more than 5% of the shares of Hudson common stock outstanding immediately prior to the Merger, to stockholders of Star, pursuant to the terms of the Merger Agreement, pursuant to Nasdaq Listing Rule 5635(a).EXTRAORDINARY TRANSACTIONSCAPITAL STRUCTUREISSUER499540AGAINST49954AGAINST128S000038991 HUDSON GLOBAL, INC.443787205US443787205808/21/2025To approve the adjournment of the Annual Meeting, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of Proposal No. 5 or to ensure that any supplemental or amended disclosure is timely provided to Hudson stockholders.CORPORATE GOVERNANCEISSUER499540AGAINST49954AGAINST128S000038991 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; Yujiro S. HataDIRECTOR ELECTIONSISSUER83350FOR8335FOR128S000038991 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; M. Garret Hampton, Ph.D.DIRECTOR ELECTIONSISSUER83350FOR8335FOR128S000038991 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; Catherine J. Mackey, Ph.D.DIRECTOR ELECTIONSISSUER83350FOR8335FOR128S000038991 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER83350FOR8335FOR128S000038991 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;SECTION 14A SAY-ON-PAY VOTESISSUER83350FOR8335FOR128S000038991 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Eric SingerDIRECTOR ELECTIONSISSUER581820WITHHOLD58182AGAINST128S000038991 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Elias NaderDIRECTOR ELECTIONSISSUER581820WITHHOLD58182AGAINST128S000038991 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: William MartinDIRECTOR ELECTIONSISSUER581820WITHHOLD58182AGAINST128S000038991 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Frederick WaschDIRECTOR ELECTIONSISSUER581820WITHHOLD58182AGAINST128S000038991 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Emily S. HoffmanDIRECTOR ELECTIONSISSUER581820WITHHOLD58182AGAINST128S000038991 IMMERSION CORPORATION452521107US452521107804/06/2026Ratification of appointment of BDO USA, P.C. as Immersion Corporation's independent registered public accounting firm for the fiscal year ending April 30, 2026.AUDIT-RELATEDISSUER581820FOR58182FOR128S000038991 IMMERSION CORPORATION452521107US452521107804/06/2026Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER581820AGAINST58182AGAINST128S000038991 INOGEN, INC.45780L104US45780L104406/05/2026Election of Class III Directors Glenn BoehnleinDIRECTOR ELECTIONSISSUER470000FOR47000FOR128S000038991 INOGEN, INC.45780L104US45780L104406/05/2026Election of Class III Directors Mira SahneyDIRECTOR ELECTIONSISSUER470000FOR47000FOR128S000038991 INOGEN, INC.45780L104US45780L104406/05/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER470000FOR47000FOR128S000038991 INOGEN, INC.45780L104US45780L104406/05/2026To approve, on an advisory and non-binding basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER470000FOR47000FOR128S000038991 INOGEN, INC.45780L104US45780L104406/05/2026To approve the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan.COMPENSATIONISSUER470000FOR47000FOR128S000038991 INOGEN, INC.45780L104US45780L104406/05/2026To approve an amendment to our Thirteenth Amended and Restated Certificate of Incorporation to declassify our Board of Directors.SHAREHOLDER RIGHTS AND DEFENSESISSUER470000FOR47000FOR128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026DIRECTOR: A. Lorne WeilDIRECTOR ELECTIONSISSUER318360FOR31836FOR128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026DIRECTOR: Michael R. ChambrelloDIRECTOR ELECTIONSISSUER318360FOR31836FOR128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026DIRECTOR: Ira H. RaphaelsonDIRECTOR ELECTIONSISSUER318360FOR31836FOR128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026DIRECTOR: Desirée G. RogersDIRECTOR ELECTIONSISSUER318360FOR31836FOR128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026DIRECTOR: Steven M. SaferinDIRECTOR ELECTIONSISSUER318360FOR31836FOR128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026DIRECTOR: Katja TautscherDIRECTOR ELECTIONSISSUER318360FOR31836FOR128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026DIRECTOR: John M. VandemoreDIRECTOR ELECTIONSISSUER318360FOR31836FOR128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers (Say-on-Pay).SECTION 14A SAY-ON-PAY VOTESISSUER318360ABSTAIN31836AGAINST128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026To approve, on an advisory basis, the frequency of the advisory vote on Say-on-Pay in future years (Say-on-Frequency).SECTION 14A SAY-ON-PAY VOTESISSUER3183601 YEAR31836AGAINST128S000038991 INSPIRED ENTERTAINMENT, INC.45782N108US45782N108105/27/2026To ratify the appointment of CBIZ CPAs P.C. as the independent auditor of the Company for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER318360FOR31836FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025DIRECTOR: Lindsay A. GardnerDIRECTOR ELECTIONSISSUER956500FOR95650FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025DIRECTOR: Antonio BonchristianoDIRECTOR ELECTIONSISSUER956500FOR95650FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025DIRECTOR: Rodrigo BoscoloDIRECTOR ELECTIONSISSUER956500FOR95650FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025DIRECTOR: Brian W. BradyDIRECTOR ELECTIONSISSUER956500FOR95650FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025DIRECTOR: John H. CaronDIRECTOR ELECTIONSISSUER956500FOR95650FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025DIRECTOR: Daniel R. RuaDIRECTOR ELECTIONSISSUER956500FOR95650FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025DIRECTOR: Patrick J. VenetucciDIRECTOR ELECTIONSISSUER956500FOR95650FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025To ratify the appointment of Grant Thornton as IZEA's independent registered public accounting firm for the fiscal year ending December 31, 2025.AUDIT-RELATEDISSUER956500FOR95650FOR128S000038991 IZEA WORLDWIDE, INC.46604H204US46604H204012/10/2025To approve on a non-binding advisory basis, the compensation paid to IZEA's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER956500FOR95650FOR128S000038991 LIGHTWAVE LOGIC INC532275104US532275104205/21/2026DIRECTOR: Thomas Connelly, Jr.DIRECTOR ELECTIONSISSUER430000FOR43000FOR128S000038991 LIGHTWAVE LOGIC INC532275104US532275104205/21/2026DIRECTOR: Laila S. PartridgeDIRECTOR ELECTIONSISSUER430000FOR43000FOR128S000038991 LIGHTWAVE LOGIC INC532275104US532275104205/21/2026Ratification of the appointment of Stephano Slack LLC to serve as the Company's Independent Registered Public Accounting Firm for fiscal year 2026.AUDIT-RELATEDISSUER430000FOR43000FOR128S000038991 NEXTDOOR HOLDINGS, INC65345M108US65345M108006/09/2026Election of Class II Director David SzeDIRECTOR ELECTIONSISSUER1660000FOR166000FOR128S000038991 NEXTDOOR HOLDINGS, INC65345M108US65345M108006/09/2026Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1660000FOR166000FOR128S000038991 NEXTDOOR HOLDINGS, INC65345M108US65345M108006/09/2026Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1660000AGAINST166000AGAINST128S000038991 OMEROS CORPORATION682143102US682143102906/18/2026Election of Directors. Thomas J. CableDIRECTOR ELECTIONSISSUER5024015960FOR50240FOR128S000038991 OMEROS CORPORATION682143102US682143102906/18/2026Election of Directors. Peter A. Demopulos, M.D.DIRECTOR ELECTIONSISSUER5024015960FOR50240FOR128S000038991 OMEROS CORPORATION682143102US682143102906/18/2026Election of Directors. Diana T. Perkinson, M.D.DIRECTOR ELECTIONSISSUER5024015960FOR50240FOR128S000038991 OMEROS CORPORATION682143102US682143102906/18/2026Approval of advisory resolution on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER5024015960FOR50240FOR128S000038991 OMEROS CORPORATION682143102US682143102906/18/2026Approval of the Amended and Restated Omeros Corporation Omnibus Incentive Compensation Plan.COMPENSATIONISSUER5024015960FOR50240FOR128S000038991 OMEROS CORPORATION682143102US682143102906/18/2026Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER5024015960FOR50240FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Lynn O'Connor VosDIRECTOR ELECTIONSISSUER771540FOR77154FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Catherine KlemaDIRECTOR ELECTIONSISSUER771540FOR77154FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: James LangDIRECTOR ELECTIONSISSUER771540FOR77154FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Patrick SpanglerDIRECTOR ELECTIONSISSUER771540FOR77154FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Mariyamma V. PrestiDIRECTOR ELECTIONSISSUER771540FOR77154FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Gregory D. WassonDIRECTOR ELECTIONSISSUER771540FOR77154FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Stephen SilvestroDIRECTOR ELECTIONSISSUER771540FOR77154FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026Advisory (non-binding) approval of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER771540FOR77154FOR128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026Approval of an amendment to the Company's 2021 Equity Incentive Plan (the "2021 Equity Plan") to increase the aggregate number of shares of Common Stock available for awards by 1,000,000 shares to 5,450,000 shares.COMPENSATIONISSUER771540AGAINST77154AGAINST128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026Approval of an amendment to the 2021 Equity Plan to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the 2021 Equity Plan.COMPENSATIONISSUER771540AGAINST77154AGAINST128S000038991 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026Ratification of Grant Thornton LLP as OptimizeRx's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER771540FOR77154FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Matthew EhrlichmanDIRECTOR ELECTIONSISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Sean KellDIRECTOR ELECTIONSISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Rachel LamDIRECTOR ELECTIONSISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Alan PickerillDIRECTOR ELECTIONSISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Amanda ReiersonDIRECTOR ELECTIONSISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Maurice TullochDIRECTOR ELECTIONSISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Camilla VelasquezDIRECTOR ELECTIONSISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Regi VengalilDIRECTOR ELECTIONSISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026To ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm for Porch Group, Inc. for the year ending December 31, 2026.AUDIT-RELATEDISSUER735500FOR73550FOR128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026To approve of, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER735500AGAINST73550AGAINST128S000038991 PORCH GROUP, INC.733245104US733245104306/10/2026To approve and adopt the Porch Group, Inc. Employee Stock Purchase Plan.CAPITAL STRUCTUREISSUER735500FOR73550FOR128S000038991 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Michael BrodskyDIRECTOR ELECTIONSISSUER1401210FOR140121FOR128S000038991 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Ian JacobsDIRECTOR ELECTIONSISSUER1401210FOR140121FOR128S000038991 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Andrew MartinDIRECTOR ELECTIONSISSUER1401210FOR140121FOR128S000038991 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Michael McConnellDIRECTOR ELECTIONSISSUER1401210FOR140121FOR128S000038991 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Steve ToweDIRECTOR ELECTIONSISSUER1401210FOR140121FOR128S000038991 POWERFLEET, INC.73931J109US73931J109709/16/2025Ratification of the appointment of Deloitte & Touche as the independent registered public accounting firm of the Company for the fiscal year ending March 31, 2026.AUDIT-RELATEDISSUER1401210FOR140121FOR128S000038991 POWERFLEET, INC.73931J109US73931J109709/16/2025Approval, on an advisory basis, of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1401210FOR140121FOR128S000038991 PRECISION BIOSCIENCES, INC.74019P207US74019P207405/21/2026DIRECTOR: Melinda BrownDIRECTOR ELECTIONSISSUER470890FOR47089FOR128S000038991 PRECISION BIOSCIENCES, INC.74019P207US74019P207405/21/2026DIRECTOR: Geno GermanoDIRECTOR ELECTIONSISSUER470890FOR47089FOR128S000038991 PRECISION BIOSCIENCES, INC.74019P207US74019P207405/21/2026Ratification of the appointment of Deloitte & Touche LLP as Precision's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER470890FOR47089FOR128S000038991 PRECISION BIOSCIENCES, INC.74019P207US74019P207405/21/2026Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers (commonly referred to as the ''say-on-pay vote'').SECTION 14A SAY-ON-PAY VOTESISSUER470890FOR47089FOR128S000038991 PRECISION BIOSCIENCES, INC.74019P207US74019P207405/21/2026Approval of the amendment and restatement of the Company's 2019 Incentive Award Plan.COMPENSATIONISSUER470890FOR47089FOR128S000038991 PRECISION BIOSCIENCES, INC.74019P207US74019P207405/21/2026Approval of an amendment to our Certificate of Incorporation to reflect changes in Delaware law regarding officer exculpation.CORPORATE GOVERNANCEISSUER470890AGAINST47089AGAINST128S000038991 PRECISION BIOSCIENCES, INC.74019P207US74019P207405/21/2026Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve any of the other proposals.CORPORATE GOVERNANCEISSUER470890AGAINST47089AGAINST128S000038991 PRIME MEDICINE, INC.74168J101US74168J101606/05/2026DIRECTOR: Michael KellyDIRECTOR ELECTIONSISSUER400000FOR40000FOR128S000038991 PRIME MEDICINE, INC.74168J101US74168J101606/05/2026DIRECTOR: David Schenkein, M.D.DIRECTOR ELECTIONSISSUER400000FOR40000FOR128S000038991 PRIME MEDICINE, INC.74168J101US74168J101606/05/2026To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER400000FOR40000FOR128S000038991 REPOSITRAK, INC.700215304US700215304411/19/2025Election of Directors: Randall K. FieldsDIRECTOR ELECTIONSISSUER24624266FOR246FOR128S000038991 REPOSITRAK, INC.700215304US700215304411/19/2025Election of Directors: Robert W. AllenDIRECTOR ELECTIONSISSUER24624266FOR246FOR128S000038991 REPOSITRAK, INC.700215304US700215304411/19/2025Election of Directors: Ronald C. HodgeDIRECTOR ELECTIONSISSUER24624266FOR246FOR128S000038991 REPOSITRAK, INC.700215304US700215304411/19/2025Election of Directors: Peter J. LarkinDIRECTOR ELECTIONSISSUER24624266FOR246FOR128S000038991 REPOSITRAK, INC.700215304US700215304411/19/2025Approval, on an advisory basis, the compensation paid to our Named Executive Officers as disclosed in this proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER24624266FOR246FOR128S000038991 REPOSITRAK, INC.700215304US700215304411/19/2025Approval, on an advisory basis, of the frequency of future Say-on-Pay votes.SECTION 14A SAY-ON-PAY VOTESISSUER246242661 YEAR246AGAINST128S000038991 REPOSITRAK, INC.700215304US700215304411/19/2025Ratification of Haynie & Company as our independent registered public accounting firm for the fiscal year ending June 30, 2026.AUDIT-RELATEDISSUER24624266FOR246FOR128S000038991 SOLITARIO RESOURCES CORP.8342EP107US8342EP107006/17/2026DIRECTOR: John LabateDIRECTOR ELECTIONSISSUER6013060FOR601306FOR128S000038991 SOLITARIO RESOURCES CORP.8342EP107US8342EP107006/17/2026DIRECTOR: James HeskethDIRECTOR ELECTIONSISSUER6013060FOR601306FOR128S000038991 SOLITARIO RESOURCES CORP.8342EP107US8342EP107006/17/2026DIRECTOR: Christopher E. HeraldDIRECTOR ELECTIONSISSUER6013060FOR601306FOR128S000038991 SOLITARIO RESOURCES CORP.8342EP107US8342EP107006/17/2026DIRECTOR: Gil AtzmonDIRECTOR ELECTIONSISSUER6013060FOR601306FOR128S000038991 SOLITARIO RESOURCES CORP.8342EP107US8342EP107006/17/2026DIRECTOR: Debbie AustinDIRECTOR ELECTIONSISSUER6013060FOR601306FOR128S000038991 SOLITARIO RESOURCES CORP.8342EP107US8342EP107006/17/2026Advisory Vote on Executive Compensation - RESOLVED THAT: Solitario shareholders approve the compensation of Solitario's Named Executive Officers, as disclosed in this Proxy Statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission set forth in Item 402 of Regulation S-K, including, but not limited to, the ''Executive Compensation'' section, the compensation tables, and any related material disclosed in the Proxy Statement for the 2026 annual meeting.SECTION 14A SAY-ON-PAY VOTESISSUER6013060FOR601306FOR128S000038991 SOLITARIO RESOURCES CORP.8342EP107US8342EP107006/17/2026Appointment of Auditors - Ratification of the Appointment of Assure CPA, LLC as Solitario's Independent Registered Public Accounting Firm for Fiscal year 2026.AUDIT-RELATEDISSUER6013060FOR601306FOR128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026DIRECTOR: Mimi K. DrakeDIRECTOR ELECTIONSISSUER392350FOR39235FOR128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026DIRECTOR: Jeffrey E. EberweinDIRECTOR ELECTIONSISSUER392350ABSTAIN39235AGAINST128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026DIRECTOR: Todd FruhbeisDIRECTOR ELECTIONSISSUER392350FOR39235FOR128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026DIRECTOR: Connia M. NelsonDIRECTOR ELECTIONSISSUER392350FOR39235FOR128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026DIRECTOR: Jennifer PalmerDIRECTOR ELECTIONSISSUER392350FOR39235FOR128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026DIRECTOR: Louis ParksDIRECTOR ELECTIONSISSUER392350FOR39235FOR128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026DIRECTOR: Robert G. PearseDIRECTOR ELECTIONSISSUER392350FOR39235FOR128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026To approve, by advisory vote, the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER392350AGAINST39235AGAINST128S000038991 STAR EQUITY HOLDINGS, INC.443787205US443787205805/27/2026To ratify the appointment of Wolf & Company, P.C. as independent registered public accounting firm to audit the Company's financial statements for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER392350FOR39235FOR128S000038991 TELA BIO, INC.872381108US872381108406/09/2026DIRECTOR: Joseph CapperDIRECTOR ELECTIONSISSUER797750ABSTAIN79775AGAINST128S000038991 TELA BIO, INC.872381108US872381108406/09/2026DIRECTOR: Betty Jo RocchioDIRECTOR ELECTIONSISSUER797750ABSTAIN79775AGAINST128S000038991 TELA BIO, INC.872381108US872381108406/09/2026DIRECTOR: William PlovanicDIRECTOR ELECTIONSISSUER797750ABSTAIN79775AGAINST128S000038991 TELA BIO, INC.872381108US872381108406/09/2026To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER797750FOR79775FOR128S000038991 TELA BIO, INC.872381108US872381108406/09/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER797750AGAINST79775AGAINST128S000038991 TELA BIO, INC.872381108US872381108406/09/2026To approve an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan, as amended, to increase the authorized shares issuable thereunder by 3,500,000 shares.COMPENSATIONISSUER797750AGAINST79775AGAINST128S000038991 TELA BIO, INC.872381108US872381108406/09/2026To approve an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 4.CORPORATE GOVERNANCEISSUER797750AGAINST79775AGAINST128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025TO SET THE NUMBER OF DIRECTORS TO BE ELECTED AT THE MEETING AT FIVE (5)AUDIT-RELATEDCORPORATE GOVERNANCEISSUER6251350FOR625135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025ELECTION OF DIRECTOR: JENNIFER TWINER MCCARRONDIRECTOR ELECTIONSISSUER6251350FOR625135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025ELECTION OF DIRECTOR: AZIM JAMALDIRECTOR ELECTIONSISSUER6251350FOR625135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025ELECTION OF DIRECTOR: DAVID LAZZARATODIRECTOR ELECTIONSISSUER6251350FOR625135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025ELECTION OF DIRECTOR: ASHA DANIEREDIRECTOR ELECTIONSISSUER6251350FOR625135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025ELECTION OF DIRECTOR: LISA COULMANDIRECTOR ELECTIONSISSUER6251350FOR625135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025RESOLVED TO APPOINT PRICEWATERHOUSECOOPERS LLP, CHARTERED PROFESSIONAL ACCOUNTANTS OF VANCOUVER, BRITISH COLUMBIA AS THE AUDITOR FOR THE COMPANY, TO HOLD OFFICE UNTIL THE NEXT ANNUAL GENERAL MEETING OF THE SHAREHOLDERS AT THE REMUNERATION TO BE FIXED BY THE COMPANYS BOARD OF DIRECTORSAUDIT-RELATEDISSUER6251350FOR625135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025RESOLVED TO RE-APPROVE THE COMPANYS EXISTING OMNIBUS SHARE COMPENSATION PLAN, AS MORE PARTICULARLY DESCRIBED IN THE ACCOMPANYING MANAGEMENT INFORMATION CIRCULARCOMPENSATIONISSUER6251350FOR625135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE RESOLUTION 1 FAVOR OR AGAINST ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE RESOLUTION 2a FAVOR OR WITHHOLD ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE RESOLUTION 2b FAVOR OR WITHHOLD ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE RESOLUTION 2c FAVOR OR WITHHOLD ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE RESOLUTION 2d FAVOR OR WITHHOLD ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE RESOLUTION 2e FAVOR OR WITHHOLD ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE RESOLUTION 3 FAVOR OR WITHHOLD ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE RESOLUTION 4 FAVOR OR AGAINST ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107512/18/2025PLEASE NOTE VOTING ABSTAIN RESOLUTIONS 2a TO 2e AND 3 WILL BE TRANSPOSED AS A WITHHOLD VOTE, TO ACCOMMODATE DIFFERING PRACTICES AND ALIGN WITH THE OFFICIAL ISSUER ANNOUNCEMENT.OTHEROther Voting MattersISSUER6251350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107501/22/2026TO CONSIDER, PURSUANT TO AN INTERIM ORDER OF THE SUPREME COURT OF BRITISH COLUMBIA DATED DECEMBER 10, 2025, AND, IF DEEMED ADVISABLE, TO PASS, WITH OR WITHOUT VARIATION, A SPECIAL RESOLUTION, THE FULL TEXT OF WHICH IS SET FORTH IN APPENDIX A TO THE MANAGEMENT INFORMATION CIRCULAR OF THE COMPANY DATED DECEMBER 11, 2025 (THE "INFORMATION CIRCULAR"), APPROVING AN ARRANGEMENT PURSUANT TO DIVISION 5 OF PART 9 OF THE BUSINESS CORPORATIONS ACT (BRITISH COLUMBIA) INVOLVING, AMONG OTHERS, THE COMPANY AND BLUE ANT MEDIA CORPORATION, IN ACCORDANCE WITH THE TERMS OF AN ARRANGEMENT AGREEMENT DATED NOVEMBER 25, 2025 BETWEEN THE COMPANY AND BLUE ANT MEDIA CORPORATION, ALL AS MORE PARTICULARLY DESCRIBED IN THE INFORMATION CIRCULARCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER5051350FOR505135FOR128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107501/22/2026PLEASE NOTE RESOLUTION 1 FAVOR OR AGAINST ARE THE ONLY AVAILABLE VOTING OPTIONSOTHEROther Voting MattersISSUER5051350128S000038991 THUNDERBIRD ENTERTAINMENT GROUP INC88605U107CA88605U107501/22/20265 JAN 2026: PLEASE NOTE THAT THIS IS A REVISION DUE TO CHANGE IN MEETING DATE FROM 12 JAN 2026 TO 22 JAN 2026. IF YOU HAVE ALREADY SENT IN YOUR VOTES, PLEASE DO NOT VOTE AGAIN UNLESS YOU DECIDE TO AMEND YOUR ORIGINAL INSTRUCTIONS. THANK YOU.OTHEROther Voting MattersISSUER5051350128S000038991 TRUECAR, INC.89785L107US89785L107012/22/2025To approve and adopt the Agreement and Plan of Merger by and among TrueCar, Inc. (the ''Company''), Fair Holdings, Inc. (''Parent'') and Rapid Merger Subsidiary, Inc. (''Merger Subsidiary'') pursuant to which, among other things, Merger Subsidiary will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (such merger, the ''Merger'' and such proposal, the ''Merger Proposal'').CORPORATE GOVERNANCEISSUER1330000FOR133000FOR128S000038991 TRUECAR, INC.89785L107US89785L107012/22/2025To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Merger (the ''Advisory Compensation Proposal'').SECTION 14A SAY-ON-PAY VOTESISSUER1330000FOR133000FOR128S000038991 TRUECAR, INC.89785L107US89785L107012/22/2025To approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if a quorum is not present or there are not sufficient votes cast at the Special Meeting to approve the Merger Proposal (the ''Adjournment Proposal'').CORPORATE GOVERNANCEISSUER1330000FOR133000FOR128S000038991 USIO, INC.917313108US917313108006/10/2026Election of Directors Ernesto R. BeyerDIRECTOR ELECTIONSISSUER4101000WITHHOLD410100AGAINST128S000038991 USIO, INC.917313108US917313108006/10/2026Election of Directors Bradley RollinsDIRECTOR ELECTIONSISSUER4101000WITHHOLD410100AGAINST128S000038991 USIO, INC.917313108US917313108006/10/2026To approve, on an advisory basis, the compensation paid to our Named Executive Officers for the year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER4101000AGAINST410100AGAINST128S000038991 USIO, INC.917313108US917313108006/10/2026To ratify the appointment of Withum Smith+Brown, PC as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER4101000FOR410100FOR128S000038991 WESTERN COPPER AND GOLD CORPORATION95805V108CA95805V108506/12/2026DIRECTOR: Raymond ThrelkeldDIRECTOR ELECTIONSISSUER1519500FOR151950FOR128S000038991 WESTERN COPPER AND GOLD CORPORATION95805V108CA95805V108506/12/2026DIRECTOR: Sandeep SinghDIRECTOR ELECTIONSISSUER1519500FOR151950FOR128S000038991 WESTERN COPPER AND GOLD CORPORATION95805V108CA95805V108506/12/2026DIRECTOR: Robert ChausseDIRECTOR ELECTIONSISSUER1519500FOR151950FOR128S000038991 WESTERN COPPER AND GOLD CORPORATION95805V108CA95805V108506/12/2026DIRECTOR: Pamela O'HaraDIRECTOR ELECTIONSISSUER1519500FOR151950FOR128S000038991 WESTERN COPPER AND GOLD CORPORATION95805V108CA95805V108506/12/2026DIRECTOR: Mark SmithDIRECTOR ELECTIONSISSUER1519500FOR151950FOR128S000038991 WESTERN COPPER AND GOLD CORPORATION95805V108CA95805V108506/12/2026DIRECTOR: Michael VittonDIRECTOR ELECTIONSISSUER1519500FOR151950FOR128S000038991 WESTERN COPPER AND GOLD CORPORATION95805V108CA95805V108506/12/2026DIRECTOR: Klaus ZeitlerDIRECTOR ELECTIONSISSUER1519500FOR151950FOR128S000038991 WESTERN COPPER AND GOLD CORPORATION95805V108CA95805V108506/12/2026Appointment of PricewaterhouseCoopers LLP as Auditors of the Corporation for the ensuing year and authorizing the Directors to fix their remuneration.AUDIT-RELATEDISSUER1519500FOR151950FOR128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To receive, consider, and adopt the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 and the reports of the directors of the Company and auditor thereon.OTHERAccept Financial Statements and Statutory ReportsISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To re-elect Mr. Qu Chen as a non-executive director.DIRECTOR ELECTIONSISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To re-elect Mr. Zhaohui Li as a non-executive director.DIRECTOR ELECTIONSISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To re-elect Ms. Hope Ni as an independent non-executive director.DIRECTOR ELECTIONSISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To authorize the board of directors of the Company to fix the remuneration of directors.COMPENSATIONISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To grant a general mandate to the directors to issue, allot, and deal with additional Class A ordinary shares of the Company (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued and outstanding shares of the Company (excluding any treasury shares) as of the date of passing of this resolution.CAPITAL STRUCTUREISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To grant a general mandate to the directors to repurchase shares and/or ADSs of the Company not exceeding 10% of the total number of issued and outstanding shares of the Company (excluding any treasury shares) as of the date of passing of this resolution.CAPITAL STRUCTUREISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To extend the general mandate granted to the directors to issue, allot, and deal with additional shares in the capital of the Company (including any sale or transfer of treasury shares out of treasury) by the aggregate number of the shares and/or shares underlying ADSs repurchased by the Company.CAPITAL STRUCTUREISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the board of directors of the Company to fix their remuneration for the year ending December 31, 2026.AUDIT-RELATEDISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026To approve the adoption of the Amended and Restated 2022 Share Incentive Plan.COMPENSATIONISSUER00128S000038991 ZHIHU, INC98955N207US98955N207106/30/2026Conditional upon the passing of resolution 7, to approve the adoption of the Service Provider Sublimit.COMPENSATIONISSUER00128S000038991 COMSCORE, INC.20564W204US20564W204412/19/2025The approval, in accordance with Nasdaq Listing Rules 5635(b) and 5635(d), of the issuance of common stock and Series C Convertible Preferred Stock ("Series C Preferred Stock") to Charter Communications Holding Company, LLC, Liberty Broadband Corporation and Pine Investor, LLC (the "Preferred Stockholders") in accordance with the Stock Exchange Agreements between the Company and each of the Preferred Stockholders (the "Share Issuance").CAPITAL STRUCTUREISSUER2837500FOR283750FOR128S000005257 COMSCORE, INC.20564W204US20564W204412/19/2025The approval of the Stock Exchange Agreements, the Certificate of Designations of the Series C Preferred Stock, the Stockholder Support Agreements with the Preferred Stockholders, an amendment to the Registration Rights Agreement with the Preferred Stockholders, the Second Amended and Restated Stockholders Agreement with the Preferred Stockholders, and the Exchange (as defined in the Stock Exchange Agreements) by a vote of the "disinterested stockholders" as defined in Delaware law (the "Disinterested Stockholder Approval").OTHERCompany Specific Organization RelatedISSUER2837500FOR283750FOR128S000005257 COMSCORE, INC.20564W204US20564W204412/19/2025The adoption of an amendment to the Amended and Restated Certificate of Incorporation to permit the Share Issuance and authorize a sufficient number of shares of common stock and preferred stock of the Company (the "COI Amendment").CAPITAL STRUCTURECORPORATE GOVERNANCEISSUER2837500FOR283750FOR128S000005257 COMSCORE, INC.20564W204US20564W204412/19/2025The approval of one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve the Share Issuance, the Disinterested Stockholder Approval and/or the COI Amendment.CORPORATE GOVERNANCEISSUER2837500FOR283750FOR128S000005257 DOXIMITY, INC26622P107US26622P107508/28/2025DIRECTOR: Jeffrey TangneyDIRECTOR ELECTIONSISSUER421000FOR42100FOR128S000005257 DOXIMITY, INC26622P107US26622P107508/28/2025DIRECTOR: Kira WamplerDIRECTOR ELECTIONSISSUER421000FOR42100FOR128S000005257 DOXIMITY, INC26622P107US26622P107508/28/2025To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending March 31, 2026.AUDIT-RELATEDISSUER421000FOR42100FOR128S000005257 DOXIMITY, INC26622P107US26622P107508/28/2025To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER421000FOR42100FOR128S000005257 FREIGHTOS LIMITEDG51405101KYG51405101312/15/2025Election of Class II Director for a three-year term expiring at the third succeeding annual general meeting of the Company (to be held in 2028): Udo LangeDIRECTOR ELECTIONSISSUER8049570FOR804957FOR128S000005257 FREIGHTOS LIMITEDG51405101KYG51405101312/15/2025Election of Class II Director for a three-year term expiring at the third succeeding annual general meeting of the Company (to be held in 2028): Rotem HershkoDIRECTOR ELECTIONSISSUER8049570FOR804957FOR128S000005257 FREIGHTOS LIMITEDG51405101KYG51405101312/15/2025Election of Class II Director for a three-year term expiring at the third succeeding annual general meeting of the Company (to be held in 2028): Michael SchaecherDIRECTOR ELECTIONSISSUER8049570FOR804957FOR128S000005257 FREIGHTOS LIMITEDG51405101KYG51405101312/15/2025Ratification of the re-appointment of Kost Forer Gabbay & Kasierer, a member firm of EY Global Limited, as the independent auditors of the Company for 2025 and authorization of the audit committee of the Board of Directors to fix the auditors' compensation.AUDIT-RELATEDISSUER8049570FOR804957FOR128S000005257 GRAB HOLDINGS LIMITEDG4124C109KYG4124C109603/24/2026Approval to amend and restate the Second Amended and Restated Memorandum and Articles of Association of the Company currently in effect and substitute in their place the Third Amended and Restated Memorandum and Articles of Association.CORPORATE GOVERNANCEISSUER00128S000005257 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Eric SingerDIRECTOR ELECTIONSISSUER1681110FOR168111FOR128S000005257 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Elias NaderDIRECTOR ELECTIONSISSUER1681110FOR168111FOR128S000005257 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: William MartinDIRECTOR ELECTIONSISSUER1681110FOR168111FOR128S000005257 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Frederick WaschDIRECTOR ELECTIONSISSUER1681110FOR168111FOR128S000005257 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Emily S. HoffmanDIRECTOR ELECTIONSISSUER1681110FOR168111FOR128S000005257 IMMERSION CORPORATION452521107US452521107804/06/2026Ratification of appointment of BDO USA, P.C. as Immersion Corporation's independent registered public accounting firm for the fiscal year ending April 30, 2026.AUDIT-RELATEDISSUER1681110FOR168111FOR128S000005257 IMMERSION CORPORATION452521107US452521107804/06/2026Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1681110FOR168111FOR128S000005257 NU HOLDINGS LTD.G6683N103KYG6683N103409/08/2025To resolve, as an ordinary resolution, that the Company's audited financial statements and the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 be approved and ratified.OTHERAccept Financial Statements and Statutory ReportsISSUER1120000FOR112000FOR128S000005257 NU HOLDINGS LTD.G6683N103KYG6683N103409/08/2025To resolve, as an ordinary resolution, that the reelection of the individuals listed from "a" to "i", as directors of the Company (the "Nominees"), be approved: a. David Vélez Osorno; b. Anita Mary Sands; c. David Alexandre Marcus; d. Douglas Mauro Leone; e. Jacqueline Dawn Reses; f. Luis Alberto Moreno Mejia; g. Roberto de Oliveira Campos Neto; h. Rogério Paulo Calderón Peres; i. Thuan Quang Pham.DIRECTOR ELECTIONSISSUER1120000FOR112000FOR128S000005257 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Michael BrodskyDIRECTOR ELECTIONSISSUER5549180FOR554918FOR128S000005257 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Ian JacobsDIRECTOR ELECTIONSISSUER5549180FOR554918FOR128S000005257 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Andrew MartinDIRECTOR ELECTIONSISSUER5549180FOR554918FOR128S000005257 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Michael McConnellDIRECTOR ELECTIONSISSUER5549180FOR554918FOR128S000005257 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Steve ToweDIRECTOR ELECTIONSISSUER5549180FOR554918FOR128S000005257 POWERFLEET, INC.73931J109US73931J109709/16/2025Ratification of the appointment of Deloitte & Touche as the independent registered public accounting firm of the Company for the fiscal year ending March 31, 2026.AUDIT-RELATEDISSUER5549180FOR554918FOR128S000005257 POWERFLEET, INC.73931J109US73931J109709/16/2025Approval, on an advisory basis, of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER5549180FOR554918FOR128S000005257 REPOSITRAK, INC.700215304US700215304411/19/2025Election of Directors: Randall K. FieldsDIRECTOR ELECTIONSISSUER1186692134FOR11866FOR128S000005257 REPOSITRAK, INC.700215304US700215304411/19/2025Election of Directors: Robert W. AllenDIRECTOR ELECTIONSISSUER1186692134FOR11866FOR128S000005257 REPOSITRAK, INC.700215304US700215304411/19/2025Election of Directors: Ronald C. HodgeDIRECTOR ELECTIONSISSUER1186692134FOR11866FOR128S000005257 REPOSITRAK, INC.700215304US700215304411/19/2025Election of Directors: Peter J. LarkinDIRECTOR ELECTIONSISSUER1186692134FOR11866FOR128S000005257 REPOSITRAK, INC.700215304US700215304411/19/2025Approval, on an advisory basis, the compensation paid to our Named Executive Officers as disclosed in this proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1186692134FOR11866FOR128S000005257 REPOSITRAK, INC.700215304US700215304411/19/2025Approval, on an advisory basis, of the frequency of future Say-on-Pay votes.SECTION 14A SAY-ON-PAY VOTESISSUER11866921343 YEARS11866FOR128S000005257 REPOSITRAK, INC.700215304US700215304411/19/2025Ratification of Haynie & Company as our independent registered public accounting firm for the fiscal year ending June 30, 2026.AUDIT-RELATEDISSUER1186692134FOR11866FOR128S000005257 TRUECAR, INC.89785L107US89785L107012/22/2025To approve and adopt the Agreement and Plan of Merger by and among TrueCar, Inc. (the ''Company''), Fair Holdings, Inc. (''Parent'') and Rapid Merger Subsidiary, Inc. (''Merger Subsidiary'') pursuant to which, among other things, Merger Subsidiary will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (such merger, the ''Merger'' and such proposal, the ''Merger Proposal'').CORPORATE GOVERNANCEISSUER940000FOR94000FOR128S000005257 TRUECAR, INC.89785L107US89785L107012/22/2025To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Merger (the ''Advisory Compensation Proposal'').SECTION 14A SAY-ON-PAY VOTESISSUER940000FOR94000FOR128S000005257 TRUECAR, INC.89785L107US89785L107012/22/2025To approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if a quorum is not present or there are not sufficient votes cast at the Special Meeting to approve the Merger Proposal (the ''Adjournment Proposal'').CORPORATE GOVERNANCEISSUER940000FOR94000FOR128S000005257 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Mortimer Berkowitz IIIDIRECTOR ELECTIONSISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Quentin BlackfordDIRECTOR ELECTIONSISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors David DemskiDIRECTOR ELECTIONSISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Karen K. McGinnisDIRECTOR ELECTIONSISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Patrick S. MilesDIRECTOR ELECTIONSISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors David R. PelizzonDIRECTOR ELECTIONSISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To elect seven persons to our Board of Directors Keith ValentineDIRECTOR ELECTIONSISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To approve the Alphatec Holdings, Inc. 2026 Equity Incentive Plan;COMPENSATIONISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To approve the Alphatec Holdings, Inc. 2026 Employee Stock Purchase Plan; andCAPITAL STRUCTUREISSUER346630FOR34663FOR128S000027365 ALPHATEC HOLDINGS, INC.02081G201US02081G201206/10/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER346630FOR34663FOR128S000027365 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. John EvansDIRECTOR ELECTIONSISSUER122000FOR12200FOR128S000027365 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. John Maraganore, Ph.D.DIRECTOR ELECTIONSISSUER122000FOR12200FOR128S000027365 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. Christi ShawDIRECTOR ELECTIONSISSUER122000FOR12200FOR128S000027365 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER122000FOR12200FOR128S000027365 BEAM THERAPEUTICS INC.07373V105US07373V105206/03/2026Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER122000FOR12200FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Marcus A. LemonisDIRECTOR ELECTIONSISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Joanna C. BurkeyDIRECTOR ELECTIONSISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Barclay F. CorbusDIRECTOR ELECTIONSISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; William B. Nettles, Jr.DIRECTOR ELECTIONSISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Debra G. PerelmanDIRECTOR ELECTIONSISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Dr. Robert J. ShapiroDIRECTOR ELECTIONSISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The election of each of Director; Joseph J. Tabacco, Jr.DIRECTOR ELECTIONSISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The approval, on an advisory (non-binding) basis, of the compensation paid by the Company to its named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock.CAPITAL STRUCTUREISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 4 and/or Proposal 6.CORPORATE GOVERNANCEISSUER210000FOR21000FOR128S000027365 BED BATH & BEYOND, INC.690370101US690370101805/14/2026The approval of an amendment and restatement of the Company's Amended and Restated 2005 Equity Incentive Plan.COMPENSATIONISSUER210000FOR21000FOR128S000027365 BRAZE, INC.10576N102US10576N102806/30/2026Election of Two Class II Directors, each to hold office until our 2029 Annual Meeting of Stockholders. Neeraj AgrawalDIRECTOR ELECTIONSISSUER105000FOR10500FOR128S000027365 BRAZE, INC.10576N102US10576N102806/30/2026Election of Two Class II Directors, each to hold office until our 2029 Annual Meeting of Stockholders. Yvonne WassenaarDIRECTOR ELECTIONSISSUER105000FOR10500FOR128S000027365 BRAZE, INC.10576N102US10576N102806/30/2026Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER105000FOR10500FOR128S000027365 BRAZE, INC.10576N102US10576N102806/30/2026To ratify the selection by the audit committee of our board of directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 31, 2027.AUDIT-RELATEDISSUER105000FOR10500FOR128S000027365 BRAZE, INC.10576N102US10576N102806/30/2026To approve an amendment to our Amended and Restated Certificate of Incorporation to provide for the exculpation of officers as permitted by recent amendments to Delaware law.CORPORATE GOVERNANCEISSUER105000FOR10500FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Business Combination Proposal - to ratify, approve, adopt and confirm the Business Combination Agreement dated as of October 27, 2025 (as amended or restated from time to time, the ''Business Combination Agreement''), by and among CEPT, Securitize, Inc. (''Securitize''), Securitize Holdings, Inc. (''PubCo''), Senna Merger Sub, Inc. (''Company Merger Sub'') and Pinecrest Merger Sub (''SPAC Merger Sub''), pursuant to which: (i) CEPT will merge with and into SPAC Merger Sub, with SPAC Merger Sub continuing as the surviving entity (the ''CEPT Merger''); and (ii) at least two (2) hours after the CEPT Merger, Company Merger Sub will merge with and into Securitize, with Securitize continuing as the surviving company (the ''PubCo Merger'' and together with the SPAC Merger, the ''Mergers''). All of the transactions contemplated by the Business Combination Agreement and any ancillary documents contemplated therein are collectively referred to as the ''Business Combination''.CORPORATE GOVERNANCEISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Merger Proposal - to approve and authorize (a) the CEPT Merger, with SPAC Merger Sub continuing as the surviving entity and the plan of merger to be entered into by SPAC Merger Sub and CEPT (the ''CEPT Plan of Merger''), and (b) upon the effective date of the CEPT Merger, (i) the memorandum and articles of association of the surviving entity in the form annexed to the CEPT Plan of Merger be approved in all respects, and (ii) the authorized share capital of CEPT be amended from $55,500 divided into 500,000,000 Class A Ordinary shares of a par value of $0.0001 each, 50,000,000 Class B ordinary shares of a par value of $0.0001 each and 5,000,000 preference shares of a par value of $0.0001 each to $50,000 divided to 500,000,000 ordinary shares of a nominal or par value of $0.0001 each.CORPORATE GOVERNANCEISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide for a classified board of directors of PubCo (the ''PubCo Board'') with three classes, designated Class I, Class II and Class III, with each class being up for election on a rolling three-year basis, subject to an initial phase-in period;SHAREHOLDER RIGHTS AND DEFENSESISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will require that the PubCo Board is elected by a plurality of the votes cast in respect of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. There shall be no cumulative voting in the election of directors;CORPORATE GOVERNANCEISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide that special meetings of the shareholders may be called only by the PubCo Board acting pursuant to a resolution adopted by a majority of the PubCo Board or by the Chair of the PubCo Board;CORPORATE GOVERNANCEISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide that a majority of the PubCo Board shall constitute a quorum for the transaction of business at any meeting of the PubCo Board and, except as otherwise expressly required by law or by the PubCo Charter, the act of a majority of the directors present at a meeting at which a quorum is present shall be the act of the PubCo Board. When a meeting is adjourned to another time or place (whether or not a quorum is present), notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the PubCo Board may transact any business which might have been transacted at the original meeting. If a quorum shall not be present at any meeting of the PubCo Board, the directors present thereat shall adjourn the meeting, from time to time, without notice other than announcement at the meeting, until a quorum shall be present;CORPORATE GOVERNANCEISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide that (a) PubCo must give written notice to shareholders entitled to vote at a meeting not less than ten (10) and not more than sixty (60) days before the date of such meeting, with such notice complying with any other requirements set by Delaware law or the Proposed Organizational Documents, and (b) at an annual meeting of the shareholders, shareholder proposals must be brought, among other things, (i) pursuant to PubCo's notice of meeting (or any supplement thereto); (ii) by or at the direction of the PubCo Board or any committee thereof duly authorized; (iii) as may be provided in the certificate of designations for any class or series of preferred stock or (iv) by any shareholder of PubCo who (A) is a shareholder of record at the time of the giving of the notice, (B) is entitled to vote at such meeting and (C) complies with the procedures set forth in the PubCo Bylaws. Additionally, for proposals to be properly brought before an annual meeting of stockholders by a stockholder, the stockholder must have given timely notice thereof in writing to the Secretary of PubCo and any such proposed business (other than the nominations of persons for election to the PubCo Board) must constitute a proper matter for stockholder action;CORPORATE GOVERNANCEISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Organizational Documents Proposals - to consider and vote, on a non-binding advisory basis, upon separate proposals to approve the material differences between the CEPT Memorandum and Articles and the Form of Certificate of Incorporation of PubCo (the ''PubCo Charter'') and the Amended and Restated Bylaws of PubCo (the ''PubCo Bylaws'' and together with the PubCo Charter, the ''Proposed Organizational Documents''), specifically consisting of the following: the Proposed Organizational Documents will provide for an exclusive forum for any filing, adjudication and trial of any action as set forth in the PubCo Charter, of the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware); provided that unless the PubCo consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for any action asserting a cause of action arising under the Securities Act of 1933, or any rule or regulation promulgated thereunder, shall be the federal district courts of the United States.CORPORATE GOVERNANCEISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Nasdaq Proposal - to approve a proposal for the purposes of complying with the applicable provisions of Nasdaq Rule 5635, the issuance (i) by CEPT of up to 535,000 CEPT Class A Ordinary Shares issuable in repayment of that certain promissory note in the aggregate principal amount of up to $1,750,000 entered into by CEPT in favor of Cantor EP Holdings II, LLC (the ''Sponsor'') on May 1, 2025 and that certain promissory note in the aggregate principal amount of up to $3,600,000 entered into by CEPT in favor of the Sponsor on May 1, 2025, and (b) up to 22,500,000 CEPT Class A Ordinary Shares (the ''PIPE Shares'') issuable to certain investors (the ''PIPE Investors'') upon consummation of a private placement immediately prior to the CEPT Merger (the ''PIPE Investment''), and (ii) by PubCo of (a) up to 156,675,245 shares of PubCo common stock in the Mergers (including up to 6,250,000 earnout shares), (b) an additional number of shares of PubCo common stock equal to 10% of the total number of shares of PubCo's Common Stock outstanding immediately following closing of the Business Combination that will, upon closing of the Business Combination, be reserved for issuance pursuant to PubCo's incentive plan and PubCo's employee stock purchase plan plus an additional number of shares of PubCo common stock that may become issuable pursuant to the exercise or settlement of certain options and restricted stock units to acquire Securitize common stock being assumed by PubCo in the Business Combination, and (c) up to 3,829,432 shares of PubCo common stock issuable upon the exercise of certain warrants held by J Digital 6 LLC, in each case, to the extent such issuances would require shareholder approval under Nasdaq Rule 5635.CAPITAL STRUCTUREISSUER180000FOR18000FOR128S000027365 CANTOR EQUITY PARTNERS II, INC.G1827P106KYG1827P106306/29/2026The Adjournment Proposal - to approve a proposal to adjourn the Meeting to a later date or dates to be determined by the Chairman of the Meeting, if it is determined by CEPT that additional time is necessary or appropriate to complete the Business Combination or for any other reason.CORPORATE GOVERNANCEISSUER180000FOR18000FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: F. E. Cohen MD, D. PhilDIRECTOR ELECTIONSISSUER106170FOR10617FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: R. Bryan RiggsbeeDIRECTOR ELECTIONSISSUER106170FOR10617FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: Suresh GunasekaranDIRECTOR ELECTIONSISSUER106170FOR10617FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: Michael D. GoldbergDIRECTOR ELECTIONSISSUER106170FOR10617FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026DIRECTOR: John W. HannaDIRECTOR ELECTIONSISSUER106170FOR10617FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER106170FOR10617FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026Approval, on an advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER106170FOR10617FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026To vote, on an advisory basis, the frequency of advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1061701 YEAR10617FOR128S000027365 CAREDX, INC.14167L103US14167L103506/11/2026Approval of an amendment to the 2024 Equity Incentive Plan.COMPENSATIONISSUER106170FOR10617FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Richard E. BullerDIRECTOR ELECTIONSISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: David F. DalveyDIRECTOR ELECTIONSISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Leo T. FurchtDIRECTOR ELECTIONSISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Lance G. LaingDIRECTOR ELECTIONSISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Polly A. MurphyDIRECTOR ELECTIONSISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Richard J. NigonDIRECTOR ELECTIONSISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Charles R. RompDIRECTOR ELECTIONSISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026DIRECTOR: Brian F. SullivanDIRECTOR ELECTIONSISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026To ratify the appointment of Boulay PLLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026To approve, on an advisory basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026To approve the Celcuity Inc. 2026 Stock Incentive Plan.COMPENSATIONISSUER48000FOR4800FOR128S000027365 CELCUITY INC.15102K100US15102K100705/14/2026To approve the Celcuity Inc. Amended and Restated Employee Stock Purchase Plan.CAPITAL STRUCTUREISSUER48000FOR4800FOR128S000027365 CIRCLE INTERNET GROUP, INC.172573107US172573107905/14/2026Election of Three Class I Directors Jeremy AllaireDIRECTOR ELECTIONSISSUER33000FOR3300FOR128S000027365 CIRCLE INTERNET GROUP, INC.172573107US172573107905/14/2026Election of Three Class I Directors Craig BroderickDIRECTOR ELECTIONSISSUER33000FOR3300FOR128S000027365 CIRCLE INTERNET GROUP, INC.172573107US172573107905/14/2026Election of Three Class I Directors P. Sean NevilleDIRECTOR ELECTIONSISSUER33000FOR3300FOR128S000027365 CIRCLE INTERNET GROUP, INC.172573107US172573107905/14/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER33000FOR3300FOR128S000027365 CIRCLE INTERNET GROUP, INC.172573107US172573107905/14/2026Advisory Vote to Approve the Frequency of Future Advisory Votes on Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER330001 YEAR3300FOR128S000027365 CIRCLE INTERNET GROUP, INC.172573107US172573107905/14/2026Ratification of the Appointment of Deloitte & Touche LLP as the Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER33000FOR3300FOR128S000027365 CODEXIS, INC.192005106US192005106706/17/2026DIRECTOR: S. G. Dilly, MBBS, PhD.DIRECTOR ELECTIONSISSUER1530460FOR153046FOR128S000027365 CODEXIS, INC.192005106US192005106706/17/2026DIRECTOR: Raymond De Vré, Ph.D.DIRECTOR ELECTIONSISSUER1530460FOR153046FOR128S000027365 CODEXIS, INC.192005106US192005106706/17/2026DIRECTOR: Rahul Singhvi, Sc.D.DIRECTOR ELECTIONSISSUER1530460FOR153046FOR128S000027365 CODEXIS, INC.192005106US192005106706/17/2026To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1530460FOR153046FOR128S000027365 CODEXIS, INC.192005106US192005106706/17/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1530460FOR153046FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2025.OTHERAccept Consolidated Financial Statements and Statutory ReportsISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the appropriation of financial results.CAPITAL STRUCTUREOTHERApprove Treatment of Net LossISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Discharge of the members of the Board of Directors and the Executive Committee.CORPORATE GOVERNANCEISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Samarth Kulkarni, Ph.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Ali Behbahani, M.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Maria Fardis, Ph.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. H. Edward Fleming, Jr., M.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Simeon J. George, M.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. John T. GreeneDIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Katherine A. High, M.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Sandesh Mahatme, LL.M.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Briggs W. Morrison, M.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Christian Rommel, Ph.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members to the Board of Directors and the Chairman. Douglas A. Treco, Ph.D.DIRECTOR ELECTIONSISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members of the Compensation Committee - Ali Behbahani, M.D.CORPORATE GOVERNANCEISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members of the Compensation Committee - H. Edward Fleming, Jr., M.D.CORPORATE GOVERNANCEISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members of the Compensation Committee - John T. GreeneCORPORATE GOVERNANCEISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the members of the Compensation Committee - Briggs W. Morrison, M.D.CORPORATE GOVERNANCEISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.COMPENSATIONISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum equity for members of the Board of Directors from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.COMPENSATIONISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027.COMPENSATIONISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026.COMPENSATIONISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders.COMPENSATIONISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2025 Compensation Report - Non-binding advisory vote on the 2025 Compensation Report.COMPENSATIONISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements.SECTION 14A SAY-ON-PAY VOTESISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of an increase to the Company's capital band.CAPITAL STRUCTUREISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of an increase to the conditional share capital for the conversion of bonds and similar debt instruments.CAPITAL STRUCTUREISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Approval of the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan.COMPENSATIONISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the independent voting rights representative.CORPORATE GOVERNANCEISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Re-election of the auditors.AUDIT-RELATEDISSUER414059FOR41FOR128S000027365 CRISPR THERAPEUTICS AGH17182108CH033408113706/04/2026Transact any other business that may properly come before the 2026 Annual General Meeting or any adjournment or postponement thereof.OTHEROther BusinessISSUER414059FOR41FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Michael Giuffre, M.D.DIRECTOR ELECTIONSISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Richard Kuntz, M.D., M.Sc.DIRECTOR ELECTIONSISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Tanya N. LewisDIRECTOR ELECTIONSISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Daniel J. O'ConnorDIRECTOR ELECTIONSISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. James ParsonsDIRECTOR ELECTIONSISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Rick PaulsDIRECTOR ELECTIONSISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. Charles Semba, M.D.DIRECTOR ELECTIONSISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To approve, on an advisory (non-binding) basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER410000FOR41000FOR128S000027365 DIAMEDICA THERAPEUTICS INC.25253X207CA25253X207705/20/2026To approve an amendment and restatement of the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan.COMPENSATIONISSUER410000FOR41000FOR128S000027365 DOXIMITY, INC26622P107US26622P107508/28/2025DIRECTOR: Jeffrey TangneyDIRECTOR ELECTIONSISSUER52000FOR5200FOR128S000027365 DOXIMITY, INC26622P107US26622P107508/28/2025DIRECTOR: Kira WamplerDIRECTOR ELECTIONSISSUER52000FOR5200FOR128S000027365 DOXIMITY, INC26622P107US26622P107508/28/2025To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending March 31, 2026.AUDIT-RELATEDISSUER52000FOR5200FOR128S000027365 DOXIMITY, INC26622P107US26622P107508/28/2025To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER52000FOR5200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Jason D. RobinsDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Harry E. SloanDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Matthew KalishDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Paul LibermanDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Woodrow H. LevinDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Jocelyn MooreDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Ryan R. MooreDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Valerie MosleyDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Steven J. MurrayDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Marni M. WaldenDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026DIRECTOR: Gregory W. WendtDIRECTOR ELECTIONSISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026To ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER182000FOR18200FOR128S000027365 DRAFTKINGS INC.26142V105US26142V105205/12/2026To conduct a non-binding advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER182000FOR18200FOR128S000027365 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026Election of Class I Directors J. Martin CarrollDIRECTOR ELECTIONSISSUER47046530FOR470FOR128S000027365 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026Election of Class I Directors Sheldon L. KoenigDIRECTOR ELECTIONSISSUER47046530FOR470FOR128S000027365 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026To approve the non-binding advisory resolution on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER47046530FOR470FOR128S000027365 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER47046530FOR470FOR128S000027365 ESPERION THERAPEUTICS, INC.29664W105US29664W105305/28/2026To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan.COMPENSATIONISSUER47046530FOR470FOR128S000027365 GRAB HOLDINGS LIMITEDG4124C109KYG4124C109603/24/2026Approval to amend and restate the Second Amended and Restated Memorandum and Articles of Association of the Company currently in effect and substitute in their place the Third Amended and Restated Memorandum and Articles of Association.CORPORATE GOVERNANCEISSUER450000FOR45000FOR128S000027365 HARROW INC.415858109US415858109406/18/2026DIRECTOR: Mark L. BaumDIRECTOR ELECTIONSISSUER103140FOR10314FOR128S000027365 HARROW INC.415858109US415858109406/18/2026DIRECTOR: Adrienne L. GravesDIRECTOR ELECTIONSISSUER103140FOR10314FOR128S000027365 HARROW INC.415858109US415858109406/18/2026DIRECTOR: Lauren P. SilvernailDIRECTOR ELECTIONSISSUER103140FOR10314FOR128S000027365 HARROW INC.415858109US415858109406/18/2026DIRECTOR: Perry J. SternbergDIRECTOR ELECTIONSISSUER103140FOR10314FOR128S000027365 HARROW INC.415858109US415858109406/18/2026To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as presented in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER103140FOR10314FOR128S000027365 HARROW INC.415858109US415858109406/18/2026Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER103140FOR10314FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102010/13/2025To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's common stock in connection with the conversion of convertible senior unsecured promissory notes due 2031 held by several non-affiliated purchasers, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of stock issued and outstanding prior to such issuance.CAPITAL STRUCTUREISSUER32121209976FOR32121FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102010/13/2025To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of the common stock issued and outstanding prior to such issuance.CAPITAL STRUCTUREISSUER32121209976FOR32121FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Craig CollardDIRECTOR ELECTIONSISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Tom CusackDIRECTOR ELECTIONSISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Sharmila Dissanaike, M.D., FACS, FCCMDIRECTOR ELECTIONSISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Craig JohnsonDIRECTOR ELECTIONSISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Michael KasetaDIRECTOR ELECTIONSISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Adam MorganDIRECTOR ELECTIONSISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Christian WaageDIRECTOR ELECTIONSISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To ratify the appointment of Withum as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To approve, on a nonbinding advisory basis, compensation paid to our Named Executive Officers during the fiscal year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To approve the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares.COMPENSATIONISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To amend the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares.CAPITAL STRUCTUREISSUER30448652611FOR304486FOR128S000027365 HERON THERAPEUTICS, INC.427746102US427746102006/11/2026To ratify, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan.SHAREHOLDER RIGHTS AND DEFENSESISSUER30448652611FOR304486FOR128S000027365 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; Yujiro S. HataDIRECTOR ELECTIONSISSUER44490FOR4449FOR128S000027365 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; M. Garret Hampton, Ph.D.DIRECTOR ELECTIONSISSUER44490FOR4449FOR128S000027365 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; Catherine J. Mackey, Ph.D.DIRECTOR ELECTIONSISSUER44490FOR4449FOR128S000027365 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER44490FOR4449FOR128S000027365 IDEAYA BIOSCIENCES, INC.45166A102US45166A102506/16/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders;SECTION 14A SAY-ON-PAY VOTESISSUER44490FOR4449FOR128S000027365 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Eric SingerDIRECTOR ELECTIONSISSUER339910FOR33991FOR128S000027365 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Elias NaderDIRECTOR ELECTIONSISSUER339910FOR33991FOR128S000027365 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: William MartinDIRECTOR ELECTIONSISSUER339910FOR33991FOR128S000027365 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Frederick WaschDIRECTOR ELECTIONSISSUER339910FOR33991FOR128S000027365 IMMERSION CORPORATION452521107US452521107804/06/2026Election of five (5) Directors: Emily S. HoffmanDIRECTOR ELECTIONSISSUER339910FOR33991FOR128S000027365 IMMERSION CORPORATION452521107US452521107804/06/2026Ratification of appointment of BDO USA, P.C. as Immersion Corporation's independent registered public accounting firm for the fiscal year ending April 30, 2026.AUDIT-RELATEDISSUER339910FOR33991FOR128S000027365 IMMERSION CORPORATION452521107US452521107804/06/2026Advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER339910FOR33991FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026Election of Directors Chris DiorioDIRECTOR ELECTIONSISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026Election of Directors Daniel GibsonDIRECTOR ELECTIONSISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026Election of Directors Umesh PadvalDIRECTOR ELECTIONSISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026Election of Directors Steve SanghiDIRECTOR ELECTIONSISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026Election of Directors Meera RaoDIRECTOR ELECTIONSISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026Election of Directors Arthur Valdez, Jr.DIRECTOR ELECTIONSISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026Election of Directors Miron WashingtonDIRECTOR ELECTIONSISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER10040FOR1004FOR128S000027365 IMPINJ, INC.453204109US453204109605/28/2026To approve the 2026 Equity Incentive Plan.COMPENSATIONISSUER10040FOR1004FOR128S000027365 KRYSTAL BIOTECH, INC.501147102US501147102705/15/2026DIRECTOR: Krish S. KrishnanDIRECTOR ELECTIONSISSUER4800FOR480FOR128S000027365 KRYSTAL BIOTECH, INC.501147102US501147102705/15/2026DIRECTOR: Christopher MasonDIRECTOR ELECTIONSISSUER4800FOR480FOR128S000027365 KRYSTAL BIOTECH, INC.501147102US501147102705/15/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER4800FOR480FOR128S000027365 KRYSTAL BIOTECH, INC.501147102US501147102705/15/2026Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER4800FOR480FOR128S000027365 KRYSTAL BIOTECH, INC.501147102US501147102705/15/2026Approval of the Company's Non-Employee Director Compensation Policy.COMPENSATIONCORPORATE GOVERNANCEISSUER4800FOR480FOR128S000027365 NEXTDOOR HOLDINGS, INC65345M108US65345M108006/09/2026Election of Class II Director David SzeDIRECTOR ELECTIONSISSUER1274000FOR127400FOR128S000027365 NEXTDOOR HOLDINGS, INC65345M108US65345M108006/09/2026Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1274000FOR127400FOR128S000027365 NEXTDOOR HOLDINGS, INC65345M108US65345M108006/09/2026Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1274000FOR127400FOR128S000027365 OMEROS CORPORATION682143102US682143102906/18/2026Election of Directors. Thomas J. CableDIRECTOR ELECTIONSISSUER275608440FOR27560FOR128S000027365 OMEROS CORPORATION682143102US682143102906/18/2026Election of Directors. Peter A. Demopulos, M.D.DIRECTOR ELECTIONSISSUER275608440FOR27560FOR128S000027365 OMEROS CORPORATION682143102US682143102906/18/2026Election of Directors. Diana T. Perkinson, M.D.DIRECTOR ELECTIONSISSUER275608440FOR27560FOR128S000027365 OMEROS CORPORATION682143102US682143102906/18/2026Approval of advisory resolution on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER275608440FOR27560FOR128S000027365 OMEROS CORPORATION682143102US682143102906/18/2026Approval of the Amended and Restated Omeros Corporation Omnibus Incentive Compensation Plan.COMPENSATIONISSUER275608440FOR27560FOR128S000027365 OMEROS CORPORATION682143102US682143102906/18/2026Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER275608440FOR27560FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Lynn O'Connor VosDIRECTOR ELECTIONSISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Catherine KlemaDIRECTOR ELECTIONSISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: James LangDIRECTOR ELECTIONSISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Patrick SpanglerDIRECTOR ELECTIONSISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Mariyamma V. PrestiDIRECTOR ELECTIONSISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Gregory D. WassonDIRECTOR ELECTIONSISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026DIRECTOR: Stephen SilvestroDIRECTOR ELECTIONSISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026Advisory (non-binding) approval of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026Approval of an amendment to the Company's 2021 Equity Incentive Plan (the "2021 Equity Plan") to increase the aggregate number of shares of Common Stock available for awards by 1,000,000 shares to 5,450,000 shares.COMPENSATIONISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026Approval of an amendment to the 2021 Equity Plan to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the 2021 Equity Plan.COMPENSATIONISSUER539350FOR53935FOR128S000027365 OPTIMIZERX CORPORATION68401U204US68401U204206/09/2026Ratification of Grant Thornton LLP as OptimizeRx's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER539350FOR53935FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Matthew EhrlichmanDIRECTOR ELECTIONSISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Sean KellDIRECTOR ELECTIONSISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Rachel LamDIRECTOR ELECTIONSISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Alan PickerillDIRECTOR ELECTIONSISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Amanda ReiersonDIRECTOR ELECTIONSISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Maurice TullochDIRECTOR ELECTIONSISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Camilla VelasquezDIRECTOR ELECTIONSISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026DIRECTOR: Regi VengalilDIRECTOR ELECTIONSISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026To ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm for Porch Group, Inc. for the year ending December 31, 2026.AUDIT-RELATEDISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026To approve of, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER623890FOR62389FOR128S000027365 PORCH GROUP, INC.733245104US733245104306/10/2026To approve and adopt the Porch Group, Inc. Employee Stock Purchase Plan.CAPITAL STRUCTUREISSUER623890FOR62389FOR128S000027365 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Michael BrodskyDIRECTOR ELECTIONSISSUER715000FOR71500FOR128S000027365 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Ian JacobsDIRECTOR ELECTIONSISSUER715000FOR71500FOR128S000027365 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Andrew MartinDIRECTOR ELECTIONSISSUER715000FOR71500FOR128S000027365 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Michael McConnellDIRECTOR ELECTIONSISSUER715000FOR71500FOR128S000027365 POWERFLEET, INC.73931J109US73931J109709/16/2025DIRECTOR: Steve ToweDIRECTOR ELECTIONSISSUER715000FOR71500FOR128S000027365 POWERFLEET, INC.73931J109US73931J109709/16/2025Ratification of the appointment of Deloitte & Touche as the independent registered public accounting firm of the Company for the fiscal year ending March 31, 2026.AUDIT-RELATEDISSUER715000FOR71500FOR128S000027365 POWERFLEET, INC.73931J109US73931J109709/16/2025Approval, on an advisory basis, of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER715000FOR71500FOR128S000027365 TELA BIO, INC.872381108US872381108406/09/2026DIRECTOR: Joseph CapperDIRECTOR ELECTIONSISSUER810000FOR81000FOR128S000027365 TELA BIO, INC.872381108US872381108406/09/2026DIRECTOR: Betty Jo RocchioDIRECTOR ELECTIONSISSUER810000FOR81000FOR128S000027365 TELA BIO, INC.872381108US872381108406/09/2026DIRECTOR: William PlovanicDIRECTOR ELECTIONSISSUER810000FOR81000FOR128S000027365 TELA BIO, INC.872381108US872381108406/09/2026To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER810000FOR81000FOR128S000027365 TELA BIO, INC.872381108US872381108406/09/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER810000FOR81000FOR128S000027365 TELA BIO, INC.872381108US872381108406/09/2026To approve an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan, as amended, to increase the authorized shares issuable thereunder by 3,500,000 shares.COMPENSATIONISSUER810000FOR81000FOR128S000027365 TELA BIO, INC.872381108US872381108406/09/2026To approve an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 4.CORPORATE GOVERNANCEISSUER810000FOR81000FOR128S000027365 VIR BIOTECHNOLOGY, INC.92764N102US92764N102805/26/2026To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal. Robert More, MBADIRECTOR ELECTIONSISSUER120000FOR12000FOR128S000027365 VIR BIOTECHNOLOGY, INC.92764N102US92764N102805/26/2026To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal. Janet Napolitano, J.D.DIRECTOR ELECTIONSISSUER120000FOR12000FOR128S000027365 VIR BIOTECHNOLOGY, INC.92764N102US92764N102805/26/2026To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal. Elliott Sigal, M.D., Ph.D.DIRECTOR ELECTIONSISSUER120000FOR12000FOR128S000027365 VIR BIOTECHNOLOGY, INC.92764N102US92764N102805/26/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER120000FOR12000FOR128S000027365 VIR BIOTECHNOLOGY, INC.92764N102US92764N102805/26/2026To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER120000FOR12000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To receive, consider, and adopt the audited consolidated financial statements of the Company as of and for the year ended December 31, 2025 and the reports of the directors of the Company and auditor thereon.OTHERAccept Financial Statements and Statutory ReportsISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To re-elect Mr. Qu Chen as a non-executive director.DIRECTOR ELECTIONSISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To re-elect Mr. Zhaohui Li as a non-executive director.DIRECTOR ELECTIONSISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To re-elect Ms. Hope Ni as an independent non-executive director.DIRECTOR ELECTIONSISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To authorize the board of directors of the Company to fix the remuneration of directors.COMPENSATIONISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To grant a general mandate to the directors to issue, allot, and deal with additional Class A ordinary shares of the Company (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued and outstanding shares of the Company (excluding any treasury shares) as of the date of passing of this resolution.CAPITAL STRUCTUREISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To grant a general mandate to the directors to repurchase shares and/or ADSs of the Company not exceeding 10% of the total number of issued and outstanding shares of the Company (excluding any treasury shares) as of the date of passing of this resolution.CAPITAL STRUCTUREISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To extend the general mandate granted to the directors to issue, allot, and deal with additional shares in the capital of the Company (including any sale or transfer of treasury shares out of treasury) by the aggregate number of the shares and/or shares underlying ADSs repurchased by the Company.CAPITAL STRUCTUREISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the board of directors of the Company to fix their remuneration for the year ending December 31, 2026.AUDIT-RELATEDISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026To approve the adoption of the Amended and Restated 2022 Share Incentive Plan.COMPENSATIONISSUER510000FOR51000FOR128S000027365 ZHIHU, INC98955N207US98955N207106/30/2026Conditional upon the passing of resolution 7, to approve the adoption of the Service Provider Sublimit.COMPENSATIONISSUER510000FOR51000FOR128S000027365